Selective S1P1 Receptor Modulators for MS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective compounds that selectively activate sphingosine-1-phosphate receptor subtype 1 (S1P1) while minimizing activation of subtype 3, which is crucial for treating conditions like multiple sclerosis, transplant rejection, and inflammatory disorders.
Innovation Solution
Development of heterocyclic compounds that act as selective S1P1 agonists, with specific structures and modifications to enhance their therapeutic index and enantiomeric purity, allowing for targeted activation of S1P1 receptors with reduced impact on S1P3 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are developed to activate S1P1 receptor, then therapeutic efficacy for multiple sclerosis and inflammatory disorders is improved, but activation of S1P3 receptor causes harmful side effects
Solution Approach 1:
The patent applies local quality by introducing specific heterocyclic structures (pyridine, pyrimidine, triazine rings) at particular positions of the molecular scaffold, and by using specific substituents (halogens, alkyl groups, alkoxy groups) to create localized regions of different chemical properties that confer selective binding to S1P1 over S1P3 receptor
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including ring size, heteroatom type, substituent position, and stereochemistry (enantiomeric purity) to optimize the compound's selectivity profile, achieving enhanced S1P1 activation with reduced S1P3 activation
2Reliability
If selective S1P1 agonists are developed, then therapeutic index is improved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional modules: a core heterocyclic scaffold (separated into options A1-A6), variable substituent groups (R1-R6), and stereocenter regions, allowing systematic optimization of each segment's contribution to selectivity while maintaining overall structural coherence
Solution Approach 2:
The patent employs composite materials by combining different heterocyclic rings (pyridine, pyrimidine, triazine) with various substituent types (halogens, alkyl, alkoxy, amino groups) to create composite molecular structures that achieve selective S1P1 agonism through synergistic interactions of multiple structural elements
3Measurement precision
If enantiomeric purity is enhanced, then selectivity for S1P1 receptor is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent applies preliminary action by incorporating chiral centers and stereoselective elements into the molecular design from the outset, and by using chiral auxiliaries or catalysts in the synthesis pathway to pre-establish the desired stereochemistry before final compound formation, thereby facilitating enantiomeric purification
Data Source
AI summary
Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.